Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Ovulation stimulation]

J Belaisch-Allart1, A Bachelot, J de Mouzon

  • 1FIVNAT, CHI Jean Rostand, Sèvres.

Contraception, Fertilite, Sexualite (1992)
|November 12, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Medical demography: Maternities are in danger. How to prepare for the future?]

Gynecologie, obstetrique, fertilite & senologie·2022
Same author

[The new Bioethics law in France].

Gynecologie, obstetrique, fertilite & senologie·2021
Same author

[Wearing a mask during childbirth: What real impact on delivery issues?]

Gynecologie, obstetrique, fertilite & senologie·2020
Same author

20 years of the European IVF-monitoring Consortium registry: what have we learned? A comparison with registries from two other regions.

Human reproduction (Oxford, England)·2020
Same author

[Comparative survey of French oocyte donor's profile and motivations between nulliparous and multiparous donors, 2017-2018].

Gynecologie, obstetrique, fertilite & senologie·2020
Same author

Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes.

Annales d'endocrinologie·2020
Same journal

[Inflammatory and/or locally advanced breast cancers. Difficulty evaluating the response to initial chemotherapy].

Contraception, fertilite, sexualite (1992)·2000
Same journal

[Proximal tubal unblocking by selective salpingography, apropos of 8 cases].

Contraception, fertilite, sexualite (1992)·2000
Same journal

[Anatomoclinical correlations of endometriosis].

Contraception, fertilite, sexualite (1992)·2000
Same journal

[Effects of raloxifene on bone loss and fracture risk in the menopausal woman].

Contraception, fertilite, sexualite (1992)·2000
Same journal

[Cytological screening of uterine cervical cancer by samples in liquid medium (CytoRich). Preliminary study of a series of 111 292 patients].

Contraception, fertilite, sexualite (1992)·2000
Same journal

[Diabetes before pregnancy, apropos of 143 cases].

Contraception, fertilite, sexualite (1992)·2000
See all related articles

New recombinant follicle-stimulating hormone (FSH) was introduced in 1997. Studies show recombinant FSH use in 20% of IVF/ICSI cases with similar pregnancy rates but fewer ampoules compared to urinary FSH.

Area of Science:

  • Reproductive Endocrinology
  • Biotechnology

Context:

  • In 1997, two novel recombinant follicle-stimulating hormone (FSH) preparations became commercially available.
  • The FIVNAT database recorded 11,000 In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI) attempts in 1997.

Purpose:

  • To evaluate the initial uptake and efficacy of recombinant FSH in assisted reproductive technologies.
  • To compare pregnancy rates and dosage requirements between recombinant FSH and traditional urinary FSH.

Summary:

  • Recombinant FSH was utilized in approximately 20% of the analyzed IVF and ICSI procedures.
  • Pregnancy success rates did not differ significantly between patients treated with recombinant FSH and those receiving urinary FSH.
  • A notable finding was the significantly lower number of ampoules required when using recombinant FSH compared to urinary FSH.

Related Experiment Videos

Impact:

  • This study provides early insights into the clinical application and resource utilization of recombinant FSH.
  • The reduced dosage suggests potential benefits in terms of patient convenience and treatment cost.
  • Findings support the growing role of recombinant gonadotropins in optimizing fertility treatments.